This is a specific type of Multiple Sclerosis. Instead of having periods of getting better and then worse (like in the more common type), this form involves a steady, slow decline in physical and mental abilities. It's a progressive disease, meaning it gets worse over time. It's different from the typical relapsing-remitting form of MS.
Every report comes from a Lived member, sent anonymously.
Have you tried Ocrevus (Ocrelizumab) for Chronic Progressive Multiple Sclerosis?
Chronic progressive multiple sclerosis (MS) is a form of MS in which nerve function gets steadily worse over time, rather than coming and going in distinct attacks. MS is a disease in which the immune system damages myelin, the protective coating around nerve fibers in the brain and spinal cord, and over time the nerve fibers themselves. In the progressive forms, that damage shows up as a slow, gradual loss of ability, most often in walking, leg strength, balance, bladder control and stamina. There are two main paths into progressive MS. In primary progressive MS (PPMS), symptoms worsen gradually from the very beginning, without clear relapses or recovery periods. In secondary progressive MS (SPMS), a person first has relapsing-remitting MS, with flare-ups followed by recovery, and later moves into a phase of steady worsening, with fewer or no relapses. The older term progressive relapsing MS is no longer used as a separate type; doctors now describe that pattern as primary progressive MS with activity. Doctors also describe progressive MS as active or not active (whether there are relapses or new inflammation on magnetic resonance imaging, or MRI, scans) and as progressing or not progressing over the past year. Those labels matter because they shape which treatments are likely to help.
No one knows exactly what causes MS. It is considered an immune-mediated disease, and several factors appear to work together to raise risk. Past infection with Epstein-Barr virus (the cause of mononucleosis) is the most consistently linked infection, although most people who have had it never develop MS. Smoking, low sun exposure and low vitamin D levels are associated with higher risk, and having a parent or sibling with MS increases the chance, although MS is not directly inherited. Why some people develop a progressive course is less clear. In secondary progressive MS, the shift tends to happen gradually after years of relapsing disease; treatment of relapsing MS can delay it, but it can still occur. Smoking is linked to a more aggressive course. Heat, fever and infections can temporarily make existing symptoms worse, but they are short-term triggers rather than causes of progression.
There is no single test for MS. A neurologist pieces together the history of symptoms, a detailed neurological examination, MRI scans of the brain and spinal cord, and sometimes a lumbar puncture (spinal tap) to look for signs of immune activity in the spinal fluid, such as antibodies called oligoclonal bands. Blood tests help rule out conditions that can look similar. Primary progressive MS is recognized after at least a year of gradually worsening symptoms, supported by findings such as typical lesions (areas of damage) on brain or spinal cord MRI, or oligoclonal bands in the spinal fluid. Because there are no sudden attacks to point to, this diagnosis often takes longer, and other causes of slow weakness or walking trouble need to be excluded. Secondary progressive MS is usually recognized in hindsight. There is no single moment or test that marks the change from relapsing to progressive disease; instead, the neurologist sees a pattern of steady worsening, independent of relapses, over months to years. Repeated examinations, walking tests and periodic MRI scans help track whether the disease is active and whether disability is increasing.
There is currently no treatment that stops or reverses progressive MS, but care has two goals: slowing the disease where a medicine can do so, and managing symptoms so daily life stays as full as possible. Disease-modifying therapies work by calming the immune attack, so they help most when there is still active inflammation. Ocrelizumab (Ocrevus) is the only disease-modifying treatment approved by the US Food and Drug Administration (FDA) for primary progressive MS. It is an antibody that removes a type of immune cell called B cells, given as an infusion into a vein every six months, or as a roughly 10-minute injection under the skin of the abdomen (Ocrevus Zunovo). In its main trial, about 33% of people on ocrelizumab had a lasting increase in disability over more than two years, compared with about 39% on placebo. That is a real but modest slowing, not a halt. Because it weakens part of the immune system, it raises the risk of infections, reduces the response to some vaccines, and means live vaccines are not recommended during treatment. For secondary progressive MS, several relapsing-MS medicines, including ocrelizumab and siponimod (Mayzent, a daily pill that keeps certain immune cells out of the brain and spinal cord), are approved for active disease, meaning there are still relapses or new MRI lesions. Siponimod requires a genetic test and a heart check before starting. In non-active progressive disease, these drugs have not shown a clear benefit, and a 2024 Cochrane review found only low-certainty evidence that any of them slow disability across progressive MS. Whether to start, continue or stop a disease-modifying drug is a decision to weigh with a neurologist. Symptom treatment and rehabilitation make a large difference regardless of disease type. Physical therapy helps maintain strength, balance and safe walking; occupational therapy helps with energy conservation and adapting tasks and the home. Medicines can ease muscle stiffness and spasms, bladder urgency, nerve pain, fatigue and depression. Dalfampridine (Ampyra), an extended-release pill, improves walking speed in some people with MS; in trials about 35 to 43% responded, compared with about 8 to 9% on placebo. Mobility aids such as a cane, brace or wheelchair can extend independence rather than signal giving up.
Progressive MS usually changes slowly, over years rather than weeks, and the pace varies a great deal from person to person. Some people stay relatively stable for long stretches, while others notice a steady decline in walking distance or stamina. Most people with MS have a normal or near-normal life expectancy, so planning is about living well with a long-term condition. Daily life often involves adapting rather than stopping: pacing activity to manage fatigue, staying cool because heat can temporarily worsen symptoms, keeping up regular exercise to protect strength and balance, and using aids when they make getting around safer or easier. Bladder and bowel changes, thinking and memory difficulties, and low mood are common and treatable, and are worth raising rather than accepting. Many people continue working with adjustments. Regular follow-up with a neurologist, usually including an annual examination and periodic MRI scans, helps judge whether the disease is active or progressing and whether treatment still makes sense. A team that may include physical and occupational therapists, a urologist, and mental health support can help as needs change.
See a neurologist if you have gradually worsening walking, leg stiffness, balance or bladder problems without a clear explanation, or if you already have MS and notice a steady decline in what you can do from year to year, since this may mean the disease course or treatment plan needs review. Contact your care team promptly if new symptoms appear or existing ones clearly worsen over a day or more (for example new weakness, numbness or vision loss), because this may be a relapse. Call them as well when symptoms flare along with a fever or burning or frequent urination, because an infection can temporarily worsen MS symptoms and, if you take an immune-suppressing treatment, may need faster attention.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Chronic Progressive Multiple Sclerosis is like, what's helped you, or ask the community a question.